In the United States, the wholesale cost of lung scarring treatment using the drug Esbriet is $7,800 per month, or $94,000 per year, says its manufacturer Roche in The New York Times. Ofev, the drug by Boehringer Ingelheim, costs $96,000 per year in America, according to FiercePharmaMarketing.
The cost of Esbriet, known as pirfenidone, is two to three times higher in America than it is in Canada and Europe, says Roche.
Boehringer Ingelheim offers up to $30,000 per year of co-pay assistance for Ofev, known as nintedanib. The company also has a patient assistance program that covers the whole cost for eligible patients who lack financial resources, according to FiercePharmaMarketing.
The Food and Drug Administration approved Esbriet and Ofey to treat idiopathic pulmonary fibrosis, a scarring of the lungs affecting 100,000 Americans. The drugs slow lung function decline in some patients, but do not cure the disease, according to The New York Times.